Skip to main content
Title Sort descending Pub Year Author SearchLink
In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms 2010 Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Journal of Korean medical science
Periodical, Abbrev.
J.Korean Med.Sci.
Pub Date Free Form
Dec
Volume
25
Issue
12
Start Page
1722
Other Pages
1726
Notes
LR: 20150205; JID: 8703518; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Pyrimidines); 0 (Triazoles); 304NUG5GF4 (Itraconazole); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); OID: NLM: PMC29952
Place of Publication
Korea (South)
ISSN/ISBN
1598-6357; 1011-8934
Accession Number
PMID: 21165285
Language
eng
SubFile
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
10.3346/jkms.2010.25.12.1722 [doi]
Output Language
Unknown(0)
PMID
21165285
Abstract
Candidaemia associated with intravascular catheter-associated infections is of great concern due to the resulting high morbidity and mortality. The antibiotic lock technique (ALT) was previously introduced to treat catheter-associated bacterial infections without removal of catheter. So far, the efficacy of ALT against Candida infections has not been rigorously evaluated. We investigated in vitro activity of ALT against Candida biofilms formed by C. albicans, C. glabrata, and C. tropicalis using five antifungal agents (caspofungin, amphotericin B, itraconazole, fluconazole, and voriconazole). The effectiveness of antifungal treatment was assayed by monitoring viable cell counts after exposure to 1 mg/mL solutions of each antibiotic. Fluconazole, itraconazole, and voriconazole eliminated detectable viability in the biofilms of all Candida species within 7, 10, and 14 days, respectively, while caspofungin and amphotericin B did not completely kill fungi in C. albicans and C. glabrata biofilms within 14 days. For C. tropicalis biofilm, caspofungin lock achieved eradication more rapidly than amphotericin B and three azoles. Our study suggests that azoles may be useful ALT agents in the treatment of catheter-related candidemia.
Descriptors
Amphotericin B/administration & dosage/pharmacology, Antifungal Agents/administration & dosage/pharmacology/therapeutic use, Biofilms/drug effects, Candida albicans/drug effects/physiology, Candida glabrata/drug effects/physiology, Candida tropicalis/drug effects/physiology, Candidiasis/drug therapy, Catheter-Related Infections/drug therapy, Catheterization, Central Venous, Drug Administration Routes, Echinocandins/administration & dosage/pharmacology, Fluconazole/administration & dosage/pharmacology, Humans, Itraconazole/administration & dosage/pharmacology, Microbial Sensitivity Tests, Pyrimidines/administration & dosage/pharmacology, Triazoles/administration & dosage/pharmacology, Voriconazole, Antibiotic Lock Technique, Biofilms, Candida
Links
Book Title
Database
Publisher
Data Source
Authors
Ko,K. S., Lee,J. Y., Song,J. H., Peck,K. R.
Original/Translated Title
URL
Date of Electronic
20101124
PMCID
PMC2995224
Editors
In vitro genoprotective and genotoxic effect of nicotine on human leukocytes evaluated by the comet assay 2014 Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University , Poznan , Poland.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Drug and chemical toxicology
Periodical, Abbrev.
Drug Chem.Toxicol.
Pub Date Free Form
Jul
Volume
37
Issue
3
Start Page
322
Other Pages
328
Notes
LR: 20151119; JID: 7801723; 0 (Reactive Oxygen Species); 6M3C89ZY6R (Nicotine); OTO: NOTNLM; 2013/11/18 [aheadofprint]; ppublish
Place of Publication
England
ISSN/ISBN
1525-6014; 0148-0545
Accession Number
PMID: 24245828
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
10.3109/01480545.2013.851693 [doi]
Output Language
Unknown(0)
PMID
24245828
Abstract
The comet assay was used to measure the DNA damage induced in vitro by nicotine in human leukocytes as the extent of DNA migration in the comet head area, tail length, percent DNA in the tail, and Olive tail moment. Samples of whole blood were collected and blood cells were challenged with acute doses of 0.1, 1 and 10 microM of (-)-nicotine for 60 minutes. We found that nicotine treatment had dose-dependent effects on the level of DNA damage. At 1 and 10 microM of nicotine, both Olive tail moment and percent DNA in the tail significantly increased (p
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Sobkowiak,R., Musidlak,J., Lesicki,A.
Original/Translated Title
URL
Date of Electronic
20131118
PMCID
Editors
In vitro method to study antifungal perfusion in Candida biofilms 2005 Oral Bioscience, Faculty of Dentistry, The University of Hong Kong, Hong Kong, SAR, People's Republic of China.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Journal of clinical microbiology
Periodical, Abbrev.
J.Clin.Microbiol.
Pub Date Free Form
Feb
Volume
43
Issue
2
Start Page
818
Other Pages
825
Notes
LR: 20140608; JID: 7505564; 0 (Antifungal Agents); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); D83282DT06 (Flucytosine); OID: NLM: PMC548120; ppublish
Place of Publication
United States
ISSN/ISBN
0095-1137; 0095-1137
Accession Number
PMID: 15695686
Language
eng
SubFile
Journal Article; IM
DOI
43/2/818 [pii]
Output Language
Unknown(0)
PMID
15695686
Abstract
Antimycotic perfusion through Candida biofilms was demonstrated by a modification of a simple in vitro diffusion cell bioassay system. Using this model, the perfusion of three commonly used antifungal agents, amphotericin B, fluconazole, and flucytosine, was investigated in biofilms of three different Candida species (i.e., Candida albicans, Candida parapsilosis, and Candida krusei) that were developed on microporous filters. Scanning electron microscopy revealed that C. albicans formed a contiguous biofilm with tightly packed blastospores and occasional hyphae compared with C. parapsilosis and C. krusei, which developed confluent biofilms displaying structural heterogeneity and a lesser cell density, after 48 h of incubation on nutrient agar. Minor structural changes were also perceptible on the superficial layers of the biofilm after antifungal perfusion. The transport of antifungals to the distal biofilm-substratum interface was most impeded by C. albicans biofilms in comparison to C. parapsilosis and C. krusei. Fluconazole and flucytosine demonstrated similar levels of perfusion, while amphotericin B was the least penetrant through all three biofilms, although the latter appeared to cause the most structural damage to the superficial cells of the biofilm compared with the other antifungals. These results suggest that the antifungal perfusion through biofilm mode of growth in Candida is dependent both on the antimycotic and the Candida species in question, and in clinical terms, these phenomena could contribute to the failure of Candida biofilm-associated infections. Finally, the in vitro model we have described should serve as a useful system to investigate the complex interactions that appear to operate in vivo within the biofilm-antifungal interphase.
Descriptors
Amphotericin B/metabolism/pharmacology, Antifungal Agents/metabolism/pharmacology, Biofilms/drug effects/growth & development, Biological Assay, Candida/classification/drug effects/growth & development/ultrastructure, Candida albicans/drug effects/growth & development/ultrastructure, Drug Resistance, Fungal, Fluconazole/metabolism/pharmacology, Flucytosine/metabolism/pharmacology, Humans, Microbial Sensitivity Tests/methods, Micropore Filters/microbiology, Microscopy, Electron, Scanning
Links
Book Title
Database
Publisher
Data Source
Authors
Samaranayake,Y. H., Ye,J., Yau,J. Y., Cheung,B. P., Samaranayake,L. P.
Original/Translated Title
URL
Date of Electronic
PMCID
PMC548120
Editors
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies 2004 Center of Excellence on Aging, Room 27, 5th level, "G. D'Annunzio" University, Via Colle dell'Ara, 66100 Chieti, Italy.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Antimicrobial Agents and Chemotherapy
Periodical, Abbrev.
Antimicrob.Agents Chemother.
Pub Date Free Form
Nov
Volume
48
Issue
11
Start Page
4453
Other Pages
4456
Notes
LR: 20141120; JID: 0315061; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Peptides, Cyclic); 0 (Pyrimidines); 0 (Triazoles); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); OID: NLM: PMC525414; pp
Place of Publication
United States
ISSN/ISBN
0066-4804; 0066-4804
Accession Number
PMID: 15504881
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
48/11/4453 [pii]
Output Language
Unknown(0)
PMID
15504881
Abstract
Time-kill and postantifungal effect (PAFE) of amphotericin B, caspofungin, fluconazole, and voriconazole were determined against clinical isolates of Candida guilliermondii, Candida kefyr, and Candida lusitaniae. Azoles displayed fungistatic activity and no measurable PAFE, regardless of the concentration tested. Amphotericin B and caspofungin demonstrated concentration-dependent fungicidal activity, although amphotericin B only produced a significant dose-dependent PAFE against all isolates tested.
Descriptors
Amphotericin B/pharmacology, Antifungal Agents/pharmacology, Candida/drug effects, Candidiasis/complications/microbiology, Colony Count, Microbial, Echinocandins, Fluconazole/pharmacology, Hematologic Neoplasms/complications, Humans, Kinetics, Microbial Sensitivity Tests, Models, Biological, Peptides, Cyclic/pharmacology, Pyrimidines/pharmacology, Triazoles/pharmacology, Voriconazole
Links
Book Title
Database
Publisher
Data Source
Authors
Di Bonaventura,G., Spedicato,I., Picciani,C., D'Antonio,D., Piccolomini,R.
Original/Translated Title
URL
Date of Electronic
PMCID
PMC525414
Editors
In vitro shear bond strength of adhesive to normal and fluoridated enamel under various contaminated conditions 1999 Department of Conservative Dentistry, Istanbul University, Faculty of Dentistry, Capa, Turkey. benderli@istanbul.edu.tr
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Quintessence international (Berlin, Germany : 1985)
Periodical, Abbrev.
Quintessence Int.
Pub Date Free Form
Aug
Volume
30
Issue
8
Start Page
570
Other Pages
575
Notes
LR: 20131121; JID: 0342677; 0 (Composite Resins); 0 (Dentin-Bonding Agents); 0 (Maleates); 0 (Phosphoric Acids); 0 (Resin Cements); 0 (Saliva, Artificial); 0 (Scotchbond Multi-Purpose); 0 (Z100 composite resin); 059QF0KO0R (Water); 7631-86-9 (Silicon Diox
Place of Publication
ENGLAND
ISSN/ISBN
0033-6572; 0033-6572
Accession Number
PMID: 10635272
Language
eng
SubFile
Comparative Study; Journal Article; D
DOI
Output Language
Unknown(0)
PMID
10635272
Abstract
OBJECTIVE: This study examined the shear bond strength of bonding agents to normal or fluoridated enamel following use of weak or strong acids to prepare enamel surfaces and after contamination with a measured amount of saliva at various stages of the bonding procedure. METHOD AND MATERIALS: One hundred extracted human third molar teeth were randomly separated into 2 basic groups (normal or fluoridated teeth), then divided into 5 subgroups. Group A specimens were not contaminated. After etching, enamel surfaces were dry and clean. Group B was left with wet surfaces after etching. Group C specimens were contaminated with artificial saliva and then dried. Group D specimens were contaminated with artificial saliva, rinsed, and then dried. In group E, all enamel surfaces were left contaminated with saliva after the etching procedures (with maleic acid or phosphoric acids). Adhesive resins were applied to all enamel surfaces according to the manufacturer's instructions. The specimens were then mounted and tested to determine shear bond strength. RESULTS: If normal enamel surfaces were rinsed and dried immediately after contamination, there was no significant reduction of shear bond strength of adhesive to enamel. Specimens in group E and group C had significantly lower bond strengths than did control specimens (group A). In the fluoridated groups etched with the phosphoric acid, statistically significant reductions in bond strengths were obtained in all contamination groups and in the control group. In the fluoridated specimens, there were no statistically significant differences between any of the contamination groups and the control group when maleic acid was used. CONCLUSION: Saliva contamination may not be a risk factor for successful bonding between bonding agent and dental tissues for normal or fluoridated enamel surfaces if they are rinsed and dried immediately after contamination. Etching of normal enamel surfaces with phosphoric acid in the presence of contamination may provide higher shear bond strength than etching with maleic acid.
Descriptors
Acid Etching, Dental/methods, Composite Resins, Dental Bonding, Dental Enamel/chemistry, Dentin-Bonding Agents, Desiccation, Fluorides/chemistry, Humans, Maleates, Materials Testing, Molar, Phosphoric Acids, Random Allocation, Resin Cements, Saliva, Artificial, Silicon Dioxide, Statistics, Nonparametric, Tensile Strength, Water/chemistry, Zirconium
Links
Book Title
Database
Publisher
Data Source
Authors
Benderli,Y., Gokce,K., Buyukgokcesu,S.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
In vitro susceptibility of amphotericin-B, voriconazole and caspofungin against Candida guilliermondii biofilms, isolated from dentals units water pipes, under different growth phases 2015 Laboratory of Antibiotics Antifungals: physico-chemistry, synthesis and biological activity, Department of Biology, Tlemcen University, BP119 Imama, Tlemcen, Algeria. Electronic address: wissame85@yahoo.fr.; Laboratory of Antibiotics Antifungals: physico-
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Journal de mycologie medicale
Periodical, Abbrev.
J.Mycol.Med.
Pub Date Free Form
Mar
Volume
25
Issue
1
Start Page
57
Other Pages
62
Notes
CI: Copyright (c) 2014; JID: 9425651; 0 (Antifungal Agents); 0 (Echinocandins); 7XU7A7DROE (Amphotericin B); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); OTO: NOTNLM; 2014/08/22 [received]; 2014/10/01 [revised]; 2014/10/30 [accepted]; 2014/11/08 [
Place of Publication
France
ISSN/ISBN
1773-0449; 1156-5233
Accession Number
PMID: 25533329
Language
eng
SubFile
Journal Article; IM
DOI
10.1016/j.mycmed.2014.10.027 [doi]
Output Language
Unknown(0)
PMID
25533329
Abstract
OBJECTIVE: The dental units water pipes are a favorable medium for biofilms formation because of the small diameter of the pipe and the duration of water stagnation, but the question which arises is the nature of the biofilms which are formed inside? This article gives a progress report on the nature of this microbial contamination and precisely the fungal biofilms formation by examining their susceptibility to antifungal agents under different growth phases. METHODS: Sixteen samples of dental units water pipes were taken from public dental clinic and from stomatology unit at the university hospital of Tlemcen (Algeria). The isolated strains were identified by the conventional mycological methods and were analyzed to determine their minimal concentrations inhibiting their growth (planktonic and sessile forms) using three antifungal agents. RESULTS: Five strains type Candida guilliermondii were identified and analyzed for their resistance to antifungal agents. Antifungal susceptibility testing demonstrated the sensitivity of all planktonic Candida guilliermondii cells against amphotericin-B, voriconzole and caspofungin but the sessile cells of these strains revealed a less susceptibility to antifungal agents and even a resistance when the biofilm made mature. CONCLUSION: Several types of yeast contaminated the dental units water pipes and especially Candida guilliermondii that was the most founded. This specie was susceptible to antifungal agents under planctonic forms and resistance where the biofilm made mature.
Descriptors
Links
Book Title
Database
Publisher
Elsevier Masson SAS
Data Source
Authors
Mazari,W., Boucherit-Otmani,Z., Boucherit,K.
Original/Translated Title
URL
Date of Electronic
20141108
PMCID
Editors
In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method 2013 Department of Medical Microbiology, Faculty of Medicine, Gaziantep University and Universite Bulvari, 27310 Gaziantep, Turkey.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
TheScientificWorldJournal
Periodical, Abbrev.
ScientificWorldJournal
Pub Date Free Form
22-Oct
Volume
2013
Issue
Start Page
236903
Other Pages
Notes
LR: 20150422; JID: 101131163; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Pyrimidines); 0 (Triazoles); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); OID: NLM: PMC3819922; 2013 [ecollection]; 2
Place of Publication
England
ISSN/ISBN
1537-744X; 1537-744X
Accession Number
PMID: 24250260
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
10.1155/2013/236903 [doi]
Output Language
Unknown(0)
PMID
24250260
Abstract
This study was performed to determine the distribution of Candida species isolated from the blood cultures of the patients hospitalized in our hospital and to investigate their antifungal susceptibility. Candida strains were identified at species level by using classical methods and API ID 32C (bioMerieux, France) identification kits. The susceptibility of the strains to amphotericin B, fluconazole, voriconazole, and caspofungin was evaluated by using the reference broth microdilution method in document M27-A3 of the Clinical and Laboratory Standards Institute. Of the 111 Candida strains isolated, 47.7% were identified as C. albicans and 52.3% as non-albicans Candida strains. The MIC ranges were 0.03-1 mug/mL for amphotericin B, 0.125->/=64 mug/mL for fluconazole, 0.03-16 mug/mL for voriconazole, and 0.015-0.25 mug/mL for caspofungin. All Candida strains were susceptible to amphotericin B and caspofungin. 10.8% isolates were resistant to fluconazole and 8.1% isolates were dose-dependent susceptible. While 0.9% isolate was resistant to voriconazole, 0.9% isolate was dose-dependent susceptible. In our study, C. albicans and C. parapsilosis were the most frequently encountered agents of candidemia and it was detected that voriconazole with a low resistance rate might also be used with confidence in the treatment of infections occurring with these agents, primarily besides amphotericin B and caspofungin.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Eksi,F., Gayyurhan,E.D., Balci,I.
Original/Translated Title
URL
Date of Electronic
20131022
PMCID
PMC3819922
Editors
In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin 2010 Clinical Microbiology Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, China Academy of Medical Science, Beijing 100730, China.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Chinese medical journal
Periodical, Abbrev.
Chin.Med.J.(Engl)
Pub Date Free Form
Oct
Volume
123
Issue
19
Start Page
2706
Other Pages
2709
Notes
LR: 20141120; JID: 7513795; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Pyrimidines); 0 (Triazoles); 304NUG5GF4 (Itraconazole); 6TK1G07BHZ (posaconazole); 7XU7A7DROE (Amphotericin B); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); ppublish
Place of Publication
China
ISSN/ISBN
0366-6999; 0366-6999
Accession Number
PMID: 21034656
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
Output Language
Unknown(0)
PMID
21034656
Abstract
BACKGROUND: During recent years, the incidence of serious infections caused by opportunistic fungi has increased dramatically due to alterations of the immune status of patients with hematological diseases, malignant tumors, transplantations and so forth. Unfortunately, the wide use of triazole antifungal agents to treat these infections has lead to the emergence of Aspergillus spp. resistant to triazoles. The present study was to assess the in vitro activities of five antifungal agents (voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin) against different kinds of Aspergillus spp. that are commonly encountered in the clinical setting. METHODS: The agar-based Etest MIC method was employed. One hundred and seven strains of Aspergillus spp. (5 species) were collected and prepared according to Etest Technique Manuel. Etest MICs were determined with RPMI agar containing 2% glucose and were read after incubation for 48 hours at 35 degrees C. MIC(50), MIC(90) and MIC range were acquired by Whonet 5.4 software. RESULTS: The MIC(90) of caspofungin against A. fumigatus, A. flavus and A. nidulans was 0.094 microg/ml whereas the MIC(90) against A. niger was 0.19 microg/ml. For these four species, the MIC(90) of caspofungin was the lowest among the five antifungal agents. For A. terrus, the MIC(90) of posaconazole was the lowest. For A. fumigatus and A. flavus, the MIC(90) in order of increasing was caspofungin, posaconazole, voriconazole, itraconazole, and amphotericin B. The MIC of amphotericin B against A. terrus was higher than 32 microg/ml in all 7 strains tested. CONCLUSIONS: The in vitro antifungal susceptibility test shows the new drug caspofungin, which is a kind of echinocandins, has good activity against the five species of Aspergillus spp. and all the triazoles tested have better in vitro activity than traditional amphotericin B.
Descriptors
Amphotericin B/pharmacology, Antifungal Agents/pharmacology, Aspergillus/drug effects, Echinocandins/pharmacology, Itraconazole/pharmacology, Microbial Sensitivity Tests, Pyrimidines/pharmacology, Triazoles/pharmacology, Voriconazole
Links
Book Title
Database
Publisher
Data Source
Authors
Shi,J. Y., Xu,Y. C., Shi,Y., Lu,H. X., Liu,Y., Zhao,W. S., Chen,D. M., Xi,L. Y., Zhou,X., Wang,H., Guo,L. N.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
Incentives for preventing smoking in children and adolescents 2012 Preventable Chronic Diseases Division, Menzies School of Health Research, Darwin, Australia. vanessa.johnston@menzies.edu.au.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The Cochrane database of systematic reviews
Periodical, Abbrev.
Cochrane Database Syst.Rev.
Pub Date Free Form
17-Oct
Volume
10
Issue
Start Page
CD008645
Other Pages
Notes
LR: 20130628; JID: 100909747; epublish
Place of Publication
England
ISSN/ISBN
1469-493X; 1361-6137
Accession Number
PMID: 23076949
Language
eng
SubFile
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1002/14651858.CD008645.pub2 [doi]
Output Language
Unknown(0)
PMID
23076949
Abstract
BACKGROUND: Adult smoking usually has its roots in adolescence. If individuals do not take up smoking during this period it is unlikely that they ever will. Further, once smoking becomes established, cessation is challenging; the probability of subsequently quitting is inversely proportional to the age of initiation. One novel approach to reducing the prevalence of youth smoking is the use of incentives. OBJECTIVES: To determine whether incentives prevent children and adolescents from starting to smoke. We also attempted to assess the dose-response of incentives, the costs of incentive programmes, whether incentives are more or less effective in combination with other interventions to prevent smoking initiation and any unintended consequences arising from the use of incentives. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group Specialized Register, with additional searches of MEDLINE, EMBASE, CINAHL, CSA databases and PsycINFO for terms relating to incentives, in combination with terms for smoking and tobacco use, and children and adolescents. The most recent searches were in May 2012. SELECTION CRITERIA: We considered randomized controlled trials allocating children and adolescents (aged 5 to 18 years) as individuals, groups or communities to intervention or control conditions, where the intervention included an incentive aimed at preventing smoking uptake. We also considered controlled trials with baseline measures and post-intervention outcomes. DATA COLLECTION AND ANALYSIS: Data were extracted by two authors and assessed independently. The primary outcome was the smoking status of children or adolescents at follow-up who reported no smoking at baseline. We required a minimum follow-up of six months from baseline and assessed each included study for risk of bias. We used the most rigorous definition of abstinence in each trial; we did not require biochemical validation of self-reported tobacco use for study inclusion. Where possible we combined eligible studies to calculate pooled estimates at the longest follow-up using the Mantel-Haenszel fixed-effect method, grouping studies by study design. MAIN RESULTS: We identified seven controlled studies that met our inclusion criteria, including participants with an age range of 11 to 14 years. Of the seven trials identified, only five had analysable data relevant for this review and contributed to the meta-analysis (6362 participants in total who were non-smokers at baseline; 3466 in intervention and 2896 in control). All bar one of the studies was a trial of the so-called Smokefree Class Competition (SFC), which has been widely implemented throughout Europe. In this competition, classes with youth generally between the ages of 11 to 14 years commit to being smoke free for a six month period. They report regularly on their smoking status; if 90% or more of the class is non-smoking at the end of the six months, the class goes into a competition to win prizes. The one study that was not a trial of the SFC was a controlled trial in which schools in two communities were assigned to the intervention, with schools in a third community acting as controls. Students in the intervention community with lower smoking rates at the end of the project (one school year) received rewards.Only one study of the SFC competition, a non-randomized controlled trial, reported a significant effect of the competition on the prevention of smoking at the longest follow-up. However, this study had a risk of multiple biases, and when we calculated the adjusted RR we no longer detected a statistically significant difference. The pooled RR for the more robust RCTs (3 studies, n = 3056 participants) suggests that, from the available data, there is no statistically significant effect of incentives to prevent smoking initiation among children and adolescents in the long term (RR 1.00, 95% CI 0.84 to 1.19). Pooled results from non-randomized trials also did not detect a significant effect, and we wer
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Johnston,V., Liberato,S., Thomas,D.
Original/Translated Title
URL
Date of Electronic
20121017
PMCID
Editors
Incentives for smoking cessation 2015 Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, UK, OX2 6GG.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The Cochrane database of systematic reviews
Periodical, Abbrev.
Cochrane Database Syst.Rev.
Pub Date Free Form
18-May
Volume
(5):CD004307. doi
Issue
5
Start Page
CD004307
Other Pages
Notes
LR: 20160602; JID: 100909747; epublish
Place of Publication
England
ISSN/ISBN
1469-493X; 1361-6137
Accession Number
PMID: 25983287
Language
eng
SubFile
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1002/14651858.CD004307.pub5 [doi]
Output Language
Unknown(0)
PMID
25983287
Abstract
BACKGROUND: Material or financial incentives are widely used in an attempt to precipitate or reinforce behaviour change, including smoking cessation. They operate in workplaces, in clinics and hospitals, and to a lesser extent within community programmes. In this third update of our review we now include trials conducted in pregnant women, to reflect the increasing activity and resources now targeting this high-risk group of smokers. OBJECTIVES: To determine whether incentives and contingency management programmes lead to higher long-term quit rates. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group Specialised Register, with additional searches of MEDLINE, EMBASE, CINAHL and PsycINFO. The most recent searches were in December 2014, although we also include two trials published in 2015. SELECTION CRITERIA: We considered randomised controlled trials, allocating individuals, workplaces, groups within workplaces, or communities to experimental or control conditions. We also considered controlled studies with baseline and post-intervention measures. We include studies in a mixed-population setting (e.g. community-, work-, institution-based), and also, for this update, trials in pregnant smokers. DATA COLLECTION AND ANALYSIS: One author (KC) extracted data and a second (JH-B) checked them. We contacted study authors for additional data where necessary. The main outcome measure in the mixed-population studies was abstinence from smoking at longest follow-up, and at least six months from the start of the intervention. In the trials of pregnant smokers abstinence was measured at the longest follow-up, and at least to the end of the pregnancy. MAIN RESULTS: Twenty-one mixed-population studies met our inclusion criteria, covering more than 8400 participants. Ten studies were set in clinics or health centres, one in Thai villages served by community health workers, two in academic institutions, and the rest in worksites. All but six of the trials were run in the USA. The incentives included lottery tickets or prize draws, cash payments, vouchers for goods and groceries, and in six trials the recovery of money deposited by those taking part. The odds ratio (OR) for quitting with incentives at longest follow-up (six months or more) compared with controls was 1.42 (95% confidence interval (CI) 1.19 to 1.69; 17 trials, [20 comparisons], 7715 participants). Only three studies demonstrated significantly higher quit rates for the incentives group than for the control group at or beyond the six-month assessment: One five-arm USA trial compared rewards- and deposit-based interventions at individual and group level, with incentives available up to USD 800 per quitter, and demonstrated a quit rate in the rewards groups of 8.1% at 12 months, compared with 4.7% in the deposits groups. A direct comparison between the rewards-based and the deposit-based groups found a benefit for the rewards arms, with an OR at 12 months of 1.76 (95% CI 1.22 to 2.53; 2070 participants). Although more people in this trial accepted the rewards programmes than the deposit programmes, the proportion of quitters in each group favoured the deposit-refund programme. Another USA study rewarded both participation and quitting up to USD 750, and achieved sustained quit rates of 9.4% in the incentives group compared with 3.6% for the controls. A deposit-refund trial in Thailand also achieved significantly higher quit rates in the intervention group (44.2%) compared with the control group (18.8%), but uptake was relatively low, at 10.5%. In the remaining trials, there was no clear evidence that participants who committed their own money to the programme did better than those who did not, or that contingent rewards enhanced success rates over fixed payment schedules. We rated the overall quality of the older studies as low, but with later trials (post-2000) more likely to meet current standards of methodology and reporting.Eight of nine trials with usable data in pre
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Cahill,K., Hartmann-Boyce,J., Perera,R.
Original/Translated Title
URL
Date of Electronic
20150518
PMCID
Editors